Breaking News
Get 40% Off 0
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolio
Close

Xilio Development Inc (XLO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Xilio Development's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.140 +0.060    +5.56%
04:00:59 - Closed. Currency in USD ( Disclaimer )
After Hours
1.091
-0.049
-4.298%
4:09:59 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 116,563
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.060 - 1.180
Xilio Development 1.140 +0.060 +5.56%

Xilio Development Inc Company Profile

 
Get an in-depth profile of Xilio Development Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

73

Equity Type

ORD

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Contact Information

Address 828 Winter Street Suite 300
Waltham, 02451
United States
Phone 857 524 2466
Fax -

Top Executives

Name Age Since Title
Jason J. Luke - 2021 Member of Scientific Advisory Board
Robert Ross - - Director
Paul J. Clancy 61 2020 Non-Employee Independent Chairman
Anthony J. O’Donoghue - - Member of Scientific Advisory Board
Deborah Charych 58 - Member of Scientific Advisory Board
Christina Rossi 46 2021 Independent Director
Yuan Xu 55 2022 Independent Director
Daniel Curran 55 2020 Independent Director
Kwok-Kin Wong - 2021 Member of Scientific Advisory Board
Andy Minn - 2021 Member of Scientific Advisory Board
Jason J. Luke - 2021 Member of Scientific Advisory Board
Robert W. Ross 49 2022 Independent Director
Christopher A. Hunter - - Member of Scientific Advisory Board
Jamie Spangler - 2021 Member of Scientific Advisory Board
Sara M. Bonstein 42 2021 Independent Director
Tomas J. Heyman 67 2022 Independent Director
Rene Russo 48 2019 President, CEO & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

XLO Comments

Write your thoughts about Xilio Development Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email